EASi-HF - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure

2024-09-03

عنوان الدراسة

EASi-HF - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) >40%

دواء الدراسة

BI 690517 , empagliflozin

رقم بروتوكول الدراسة

1378-0020

حالة الدراسة

Ongoing

موقع الدراسة

King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh),King Abdulaziz Medical City NG (Riyadh), King Abdulaziz University Hospital (Jeddah)

مرحلة الدراسة

An official government website affiliated with the Government of the Kingdom of Saudi Arabia.

Official Saudi government website domains end with gov.sa

Government websites use the protocol. HTTPS for encryption and security.

Registered with the Digital Government Authority under number:

Suggestions

EASi-HF - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure

EASi-HF - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure